In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...
A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...
Everyday Health on MSN
Who should be on your large B-cell lymphoma care team?
Having a well-rounded care team can make large B-cell lymphoma treatment easier. Learn how nurses, social workers, and other ...
Everyday Health on MSN
How supportive care fits into large B-cell lymphoma treatment
Explore the benefits of supportive care in large B-cell lymphoma treatment. Learn how it can ease symptoms, boost quality of life, and more.
Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...
During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.
Incyte (INCY) stock and Xencor (XNCR) stock are in focus as jointly developed antibody drug tafasitamab succeeds in a ...
Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...
Incyte said on Monday its experimental combo therapy helped patients with a type of blood cancer live longer without their ...
Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...
US biotech Incyte (Nasdaq: INCY) yesterday announced positive top-line results from the pivotal Phase III frontMIND trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback